고형암 (전체) · EGFR

8개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved8 programs
AntibodyLimited DatastaleHuiKai LiPhase 2

Pucotenlimab (Pucotenlimab)

Biliary Tract Cancer (BTC); EGFR-positive Advanced Biliary Tract Carcinoma · Nasopharyngeal Cancinoma (NPC)

#NasopharyngealCancinomaNPC#Antibody#Phase2#monoclonal-antibody#BiliaryTractCancerBTC+2
Trials 42Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

CART-EGFR (CART-EGFR)

Advanced EGFR-positive Solid Tumors · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 9Status Active
AntibodyLimited DatastaleRoswell Park Cancer InstitutePhase 1

Nimotuzumab (Nimotuzumab)

EGFR Gene Mutation; Recurrent Non-Small Cell Lung Carcinoma · Advanced Cancer

#AdvancedCancer#Antibody#Phase1#monoclonal-antibody#EGFRGeneMutation+2
Trials 2Status Active
ADCLimited DatastaleThe Netherlands Cancer InstitutePhase 2

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

Non-Small Cell Lung Carcinoma; Advanced Non-Small Cell Squamous Lung Cancer · EGFR

#EGFR#ADC#Phase2#antibody-drug-conjugate#Non-SmallCellLungCarcinoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleBenaroya Research InstitutePhase 2

Panitumumab or Cetuximab (Anti-EGFR, Anti-EGFR (Panitumumab or Cetuximab))

Colorectal Cancer; Cholangiocarcinoma · EGFR

#EGFR#Antibody#Phase2#monoclonal-antibody#ColorectalCancer+2
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

EGFR/HER2 Dual-Target CAR-NK Cells (EGFR/HER2 Dual-Target CAR-NK Cells)

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma; Biomarker-positive EGFR/HER2- Expressing HNSCC · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 1

TGFβR-KO CAR-EGFR T Cells (TGFβR-KO CAR-EGFR T Cells)

Solid Tumor, Adult; EGFR Overexpression · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleShanghai Cell Therapy Research …Phase 2

anti-CTLA-4/PD-1 expressing EGFR-CAR-T (anti-CTLA-4/PD-1 expressing EGFR-CAR-T)

Advanced Solid Tumor · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active